New Zealand Approves MDMA for Severe PTSD — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Medsafe approved two psychiatrists on Friday to prescribe pharmaceutical-grade MDMA to patients with severe PTSD, making New Zealand the second country worldwide to allow the treatment after Australia approved it in 2023.
- Deputy Prime Minister David Seymour backed the move, stating "PTSD ruins lives and is difficult to treat" and that "MDMA can be very effective at treating it through psychedelic-assisted therapy."
- New Zealand's Ministry of Health said treatment will be administered alongside psychotherapy in a controlled clinical setting, patients will not be supplied drugs to take home, and patients must be aged 18 or older.
- The US FDA rejected legalizing MDMA's medicinal use in 2024, citing insufficient evidence of safety and efficacy, though clinical trials continue; current US pharmaceutical PTSD options are limited to two antidepressants requiring three months of dosing with uneven response rates.
- A study in Israel last year found that MDMA taken by partygoers at the Nova music festival during the October 7 Hamas attacks had helped cushion the trauma they endured.
- Seymour last year backed New Zealand's approval of psilocybin (magic mushrooms) for severe depression, framing the MDMA decision as part of a broader push toward "innovative treatments."
Why it matters: Only two psychiatrists are cleared to prescribe at launch, so access stays extremely limited despite nationwide approval. New Zealand and Australia now stand alone after the FDA rejected MDMA's medicinal use in 2024 for insufficient evidence, leaving US PTSD patients reliant on two antidepressants that require three months of dosing with uneven response rates.
Ask SkimNews
